Virve Korhonen's research while affiliated with Tampere University Hospital (TAUH) and other places

Publications (4)

Article
Full-text available
Treatment of multi-drug resistant tuberculosis (MDR-TB) is a global challenge requiring long treatment with costly drugs. We assessed treatment combinations, outcome and the utility of whole genome sequencing (WGS) in MDR-TB cases. Clinical, demographic, and microbiological data were obtained of all patients with MDR-TB who started treatment in Fin...
Article
Full-text available
Background: Major transition in tuberculosis (TB) epidemiology is taking place in many European countries including Finland. Monitoring treatment outcome of TB cases is important for identifying gaps in the national TB control program, in order to strengthen the system. The aim of the study was to identify potential risk factors for non-successful...
Article
Full-text available
Background We investigated the epidemiology and prevalence of potential risk factors of tuberculosis (TB) recurrence in a population-based registry cohort of 8084 TB cases between 1995 and 2013. Methods An episode of recurrent TB was defined as a case re-registered in the National Infectious Disease Register at least 360 days from the date of the i...
Article
Recurrent tuberculosis (TB) is caused by an endogenous re-activation of the same strain of Mycobacterium tuberculosis (relapse) or exogenous infection with a new strain (re-infection). Recurrence of TB in Finland was analysed in a population-based, 19-year study, and genotyping was used to define relapse and re-infection. The M. tuberculosis isolat...

Citations

... We need to improve our treatment program as for almost one fifth of our cases MDR-TB treatment was interrupted or the patient transferred to another country during treatment resulting in high risk of treatment interruption. On the other hand, our treatment success rate of 71% among pulmonary MDR-TB cases is close to the rate published earlier for pulmonary non-MDR TB cases in Finland [26]. Nevertheless, direct conclusions between MDR and non-MDR cases cannot be made as demographics among these two cohorts differ substantially; MDR cases are much younger, have less comorbidities and are more often of foreign origin [26]. ...
... A WHO report estimated that 6.8% of TB cases recurred worldwide in 2019 [11], and recurrence occurs not only in high TB incidence countries, but also in low countries [12][13][14]. A retrospective study of surveillance data and clinical records in Finland showed 0.6% of TB cases were recurrent from 1995 to 2013 [15], and 1.3% of TB cases were recurrent in Barcelona from 2003 to 2006 [12], and the proportion of recurrent cases between 4.2 and 5.7% in the United States during 1993-2010 [16]. In addition, 5.3% of successfully treated bacteriologically confirmed cases had a recurrence in Shanghai [5], China, and 6.8% in Beijing [6]. ...
... [41] Recent studies have used WGS to evaluate paired samples, comparing SNP differences between the original and new infection following treatment; however, the results are variable results. [42][43][44][45] While the capacity to generate WGS data has grown substantially, over the last few years, our understanding of how best to use these data is still not clear. [46,47] In a recent study by RIFAQUIN investigators, WGS was evaluated for identifying new infections in treated patients as either relapses or reinfections and compared with mycobacterial interspersed repetitive units-variable number tandem repeats (MIRU-VNTR) typing. ...